EGFR and non-small cell lung carcinoma: This analysis revealed a significant overexpression of LAPTM4B in EGFR-mutant NSCLC tumors (Fig. 1A), most prominently in cases harboring L861Q mutation and exon 19 deletions (Fig. 1B).